2012/67/EU: Commission Implementing Decision of 3 February 2012 amending Decision 2008/911/EC establishing a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (notified under document C(2012) 514) Text with EEA relevance

Decision 2008/911/EC · Decision · 3 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Annexes I and II to Decision 2008/911/EC are amended in accordance with the Annex to this Decision.

Article 2

This Decision is addressed to the Member States.

Supplementary provisions

ANNEXSupplementary provisions

ANNEX Decision 2008/911/EC is amended as follows: (1) in Annex I, the following substance is inserted after Pimpinella anisum L.: ‘ Thymus vulgaris L., Thymus zygis Loefl. ex L., aetheroleum’; (2) in Annex II, the following is inserted after the entry on Pimpinella anisum L.: ‘ COMMUNITY LIST ENTRY ON THYMUS VULGARIS L., THYMUS ZYGIS LOEFL. EX L., AETHEROLEUM Scientific name of the plant Thymus vulgaris L., Thymus zygis Loefl. ex L. Botanical family Lamiaceae Herbal preparation(s) Essential oil obtained by steam distillation from the fresh flowering aerial parts of Thymus vulgaris L., Thymus zygis Loefl. ex L. or a mixture of both species European Pharmacopoeia monograph reference 01/2008:1374 Indication(s) Traditional herbal medicinal product for the relief of symptoms in coughs and colds. The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use. Type of tradition European Specified strength Please see “Specified posology” Specified posology Adults and elderly Cutaneous use: in liquid and semi-solid dosage forms in concentrations up to 10 %; apply up to 3 times daily. Use as bath additive: 0,007-0,025 g per litre. Adolescents Use as bath additive: 0,007-0,025 g per litre Children 6-12 years Use as bath additive: 0,0035-0,017 g per litre Children 3-6 years Use as bath additive: 0,0017-0,0082 g per litre One bath every day or every second day. The cutaneous use in children and adolescents under 18 years of age is not recommended (see section “Special warnings and precaution for use”). The use as bath additive in children under 3 years of age is not recommended (see section “Special warnings and precaution for use”). Route of administration Cutaneous use: apply to the chest and the back. Use as a bath additive: recommended temperature of bath: 35-38 °C. Duration of use or any restrictions on the duration of use Duration of a bath: 10-20 minutes. If the symptoms persist longer than 1 week, a doctor or a qualified health care practitioner should be consulted. Any other information necessary for the safe use Contraindications Hypersensitivity to the active substance. Use as bath additive: Full baths are contraindicated in cases of open wounds, large skin injuries, acute skin diseases, high fever, severe infections, severe circulatory disturbances and cardiac insufficiency. Special warnings and precautions for use Cutaneous use: Like other essential oils Thyme oil should not be applied to the face particularly in the nasal area of babies and infants under the age of 2 years because of the risk of a laryngospasm. When dyspnoea, fever or purulent sputum occurs, a doctor or a qualified health care practitioner should be consulted. The use in children and adolescents under 18 years of age is not recommended due to lack of adequate data. Use as bath additive: When dyspnoea, fever or purulent sputum occurs, a doctor or a qualified health care practitioner should be consulted. The use in children under 3 years of age is not recommended because medical advice should be sought and due to lack of adequate data. In cases of hypertension, a full bath should be used with caution. Interactions with other medicinal products and other forms of interaction None reported. Pregnancy and lactation Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. Effects on ability to drive and use machines No studies on the effect on the ability to drive and use machines have been performed. Undesirable effects Hypersensitivity reactions and skin irritation have been observed. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted. Overdose No case of overdose has been reported. Pharmaceutical particulars [If necessary] Not applicable. Pharmacological effects or efficacy plausible on the basis of long-standing use and experience [If necessary for the safe use of the product] Not applicable.’

Other acts of the same type

Council Decision (EU) 2021/793 of 26 March 2021 on the signing, on behalf of the European Union, and provisional application of the Sustainable Fisheries Partnership Agreement between the European Union, of the one part, and the Government of Greenland and the Government of Denmark, of the other part, and the implementing Protocol thereto Commission Decision (EU) 2021/534 of 24 March 2021 determining under Article 39(1) of Directive 2014/33/EU of the European Parliament and of the Council whether a measure taken by Germany to prohibit the placing on the market of a lift model manufactured by Orona is justified or not (notified under document C(2021) 1863) (Text with EEA relevance)Decision (EU) 2021/536 of the European Parliament and of the Council of 24 March 2021 amending Council Decision 2008/971/EC as regards the equivalence of forest reproductive material produced in the United Kingdom (Text with EEA relevance)Decision (EU) 2021/537 of the European Parliament and of the Council of 24 March 2021 amending Council Decisions 2003/17/EC and 2005/834/EC as regards the equivalence of field inspections and the equivalence of checks on practices for the maintenance of varieties of agricultural plant species carried out in the United Kingdom (Text with EEA relevance)Council Decision (CFSP) 2021/481 of 22 March 2021 amending Decision (CFSP) 2020/1999 concerning restrictive measures against serious human rights violations and abuses Council Decision (CFSP) 2021/482 of 22 March 2021 amending Decision 2013/184/CFSP concerning restrictive measures against Myanmar/Burma Council Decision (CFSP) 2021/483 of 22 March 2021 amending Decision 2013/184/CFSP concerning restrictive measures against Myanmar/Burma Council Decision (CFSP) 2021/487 of 22 March 2021 amending and extending Decision (CFSP) 2018/653 on the establishment of a warehouse capability for civilian crisis-management missions Commission Implementing Decision (EU) 2021/488 of 22 March 2021 amending Implementing Decisions (EU) 2020/174 and (EU) 2020/1167 as regards the use of the approved innovative technologies in certain passenger cars and in light commercial vehicles capable of running on liquefied petroleum gas, compressed natural gas and E85 (Text with EEA relevance)Council Decision (CFSP) 2021/509 of 22 March 2021 establishing a European Peace Facility, and repealing Decision (CFSP) 2015/528 Council Decision (EU) 2021/510 of 22 March 2021 amending Decision 1999/70/EC concerning the external auditors of the national central banks, as regards the external auditors of the Deutsche Bundesbank Council Decision (EU) 2021/511 of 22 March 2021 amending Decision 1999/70/EC concerning the external auditors of the national central banks, as regards the external auditors of Eesti Pank

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

What to look at next

Browse all EU Legal ActsEvery instrument by type and year, full text free to read section by sectionEuropean Union legislation EU Legal Acts by type and yearGrouped by instrument type and year of enactment, so you can find others of the same kindBrowse by type and year European Union: what this database coversWhich datasets are here, which official source they come from, and how current they areEuropean Union overview